Do you know your risk for a stroke?

Get the right stroke tests to examine your cardiovascular health and your know your risk for stroke with Ulta Lab Tests.

If you’re like most people, the answer is probably no. But it’s not too late to find out! Ulta Lab Tests offers a variety of blood tests that can help identify cardiovascular health risks and monitor your progress over time.

The American Stroke Association reports that every 40 seconds, someone in the United States has a stroke. That’s why it is so important to be aware of your cardiovascular health and take proactive steps to prevent strokes from happening. You may be at risk if you have high blood pressure, diabetes, heart disease, or smoke cigarettes. If left untreated, a stroke could lead to paralysis or even death. The best way to prevent this from happening is by taking proactive steps like getting tested with Ulta Lab Tests today!

Ulta Lab Tests offers affordable blood tests that can help you monitor your cardiovascular health and screen for potential risks of heart disease, diabetes, high cholesterol, and more. You can order online from home or work 24 hours a day, 7 days per week. Our tests are fast – results come back within 24-48 hours for most tests! And our lab partner, Quest, provides excellent standards for accuracy and precision when testing blood samples. You can trust us with your most personal information because we use advanced encryption technology to keep all data secure on our servers at all times—and offer a guarantee of confidentiality too!

Order one or more tests today from Ulta Lab Tests!

Select the article below to learn more about stroke and lab tests that can be used to assess risk.

Stroke and Lab Testing: What You Need to Know

Name Matches
Screening test for deficiencies of plasma coagulation factors other than Factors VII and XIII. The test is also used to monitor patients on heparin therapy.

Screening test for abnormalities of coagulation factors that are involved in the extrinsic pathway. Also used to monitor effects of Warfarin therapy and to study patients with hereditary and acquired clotting disorders.

PT-Screening test for deficiencies of plasma coagulation factors other than Factors VII and XIII. The test is also used to monitor patients on heparin therapy. PTT-Screening test for abnormalities of coagulation factors that are involved in the extrinsic pathway. Also used to monitor effects of Warfarin therapy and to study patients with hereditary and acquired clotting disorders.

A Complete Blood Count (CBC) Panel is used as a screening test for various disease states including anemia, leukemia, and inflammatory processes.

A CBC blood test includes the following biomarkers: WBC, RBC, Hemoglobin, Hematocrit, MCV, MCH, MCHC, RDW, Platelet count, Neutrophils, Lymphs, Monocytes, Eos, Basos, Neutrophils (Absolute), Lymphs (Absolute), Monocytes(Absolute), Eos (Absolute), Basos (Absolute), Immature Granulocytes, Immature Grans (Abs)

NOTE: Only measurable biomarkers will be reported.

Reflex Parameters for Manual Slide Review
  Less than  Greater Than 
WBC  1.5 x 10^3  30.0 x 10^3 
Hemoglobin  7.0 g/dL  19.0 g/dL 
Hematocrit  None  75%
Platelet  100 x 10^3  800 x 10^3 
MCV  70 fL  115 fL 
MCH  22 pg  37 pg 
MCHC  29 g/dL  36.5 g/dL 
RBC  None  8.00 x 10^6 
RDW  None  21.5
Relative Neutrophil %  1% or ABNC <500  None 
Relative Lymphocyte %  1% 70%
Relative Monocyte %  None  25%
Eosinophil  None  35%
Basophil  None  3.50%
Platelet  <75 with no flags,
>100 and <130 with platelet clump flag present,
Instrument Flags Variant lymphs, blasts,
immature neutrophils,  nRBC’s, abnormal platelets,
giant platelets, potential interference
The automated differential averages 6000+ cells. If none of the above parameters are met, the results are released without manual review.
CBC Reflex Pathway

Step 1 - The slide review is performed by qualified Laboratory staff and includes:

  • Confirmation of differential percentages
  • WBC and platelet estimates, when needed
  • Full review of RBC morphology
  • Comments for toxic changes, RBC inclusions, abnormal lymphs, and other
  • significant findings
  • If the differential percentages agree with the automated counts and no abnormal cells are seen, the automated differential is reported with appropriate comments

Step 2 - The slide review is performed by qualified Laboratory staff and includes: If any of the following are seen on the slide review, Laboratory staff will perform a manual differential:

  • Immature, abnormal, or toxic cells
  • nRBC’s
  • Disagreement with automated differential
  • Atypical/abnormal RBC morphology
  • Any RBC inclusions

Step 3 If any of the following are seen on the manual differential, a Pathologist will review the slide:

  • WBC<1,500 with abnormal cells noted
  • Blasts/immature cells, hairy cell lymphs, or megakaryocytes
  • New abnormal lymphocytes or monocytes
  • Variant or atypical lymphs >15%
  • Blood parasites
  • RBC morphology with 3+ spherocytes, RBC inclusions, suspect Hgb-C,
  • crystals, Pappenheimer bodies or bizarre morphology
  • nRBC’s

Most Popular
Serum glucose levels may be abnormally high (hyperglycemia) or abnormally low (hypoglycemia). Glucose measurements are used in the diagnosis and treatment of carbohydrate metabolic disorders including diabetes mellitus, idiopathic hypoglycemia, and pancreatic islet cell neoplasm.

Comprehensive Metabolic Panel

A lipid panel includes:Total cholesterol —this test measures all of the cholesterol in all the lipoprotein particles.High-density lipoprotein cholesterol (HDL-C) — measures the cholesterol in HDL particles; often called "good cholesterol" because it removes excess cholesterol and carries it to the liver for removal.Low-density lipoprotein cholesterol (LDL-C) — calculates the cholesterol in LDL particles; often called "bad cholesterol" because it deposits excess cholesterol in walls of blood vessels, which can contribute to atherosclerosis. Usually, the amount of LDL cholesterol (LDL-C) is calculated using the results of total cholesterol, HDL-C, and triglycerides.Triglycerides — measures all the triglycerides in all the lipoprotein particles; most is in the very low-density lipoproteins (VLDL).Very low-density lipoprotein cholesterol (VLDL-C) — calculated from triglycerides/5; this formula is based on the typical composition of VLDL particles.Non-HDL-C — calculated from total cholesterol minus HDL-C.Cholesterol/HDL ratio — calculated ratio of total cholesterol to HDL-C.

Cardiolipin Antibodies (IgA, IgG, IgM)

  • Cardiolipin Antibody (IgA) 
  • Cardiolipin Antibody (IgG) 
  • Cardiolipin Antibody (IgM) 

Cardiolipin antibodies (CA) are seen in a subgroup of patients with autoimmune disorders, particularly systemic lupus erythematosus (SLE), who are at risk for vascular thrombosis, thrombocytopenia, cerebral infarct and/or recurrent spontaneous abortion. Elevations of CA associated with increased risk have also been seen in idiopathic thrombocytopenic purpura, rheumatoid and psoriatic arthritis, and primary Sjögren's syndrome.

Antinuclear antibodies are associated with rheumatic diseases including Systemic Lupus Erythematous (SLE), mixed connective tissue disease, Sjogren's syndrome, scleroderma, polymyositis, CREST syndrome, and neurologic SLE. 

Reflex Information: If ANA Screen, IFA is positive, then ANA Titer and Pattern will be performed at an additional charge.

Troponin I is part of a protein complex which regulates the contraction of striated muscle. In acute coronary syndromes (ACS), it can be detected in blood at 4-8 hours following the onset of chest pain, reaches a peak concentration at 12-16 hours, and remains elevated for 5-9 days. Troponin I has been used as a reliable marker in the diagnosis of perioperative myocardial infarction in patients undergoing cardiac surgery.

Test for myocardial infarction and skeletal muscle damage. Elevated results may be due to: myocarditis, myocardial infarction (heart attack), muscular dystrophy, muscle trauma or excessive exercise

Aids in diagnosis of decreased activity of Protein C characterized by recurrent venous thrombosis. Acquired deficiencies associated with Protein C include: oral anticoagulant therapy, liver disease, vitamin K deficiency, malignancy, consumptive DIC, surgery, trauma, antibodies to Protein C and hepatic immaturity of the newborn.

Preferred test in patients with Lupus anticoagulant, on heparin or direct thrombin inhibitors, or on Factor VIII concentrates.

Useful in differentiating inflammatory and neoplastic diseases and as an index of disease severity. CRP is also useful in monitoring inflammatory disease states.

Syphilis (RPR + FTA-ABS)

  • FTA-ABS - Treponema pallidum Ab (Confirmation for Syphilis RPR test).
  • Syphilis RPR ( RPR (Monitor) with Reflex to Titer)

FTA-ABS - Treponema pallidum Ab

Clinical Significance

The FTA-ABS is a specific treponemal assay to detect antibody to t. Pallidum. The FTA-ABS becomes reactive 4-6 weeks after infection. Unlike the nontreponemal tests, once the FTA-ABS test becomes reactive, it will remain reactive for many years. Since the reactivity found with the FTA-ABS does not indicate response to therapy, it is not suitable for monitoring treatment. The FTA-ABS test does not distinguish between syphillis and other treponematoses such as yaws, pinta and bejil.

The treponemal antibody test (FTA-ABS) is often used as an initial test. A positive result indicates the presence of syphilis antibodies in the blood, but since treponemal antibodies remain positive even after an infection has been treated, it does not indicate whether the person has a current infection or was infected in the past. Conversely, nontreponemal antibodies as detected with an RPR typically disappear in an adequately treated person after about 3 years. Thus, if an initial treponemal test is positive, an RPR can be performed to differentiate between an active or past infection. In this case, a positive RPR would confirm that the person has been exposed to syphilis and, if not treated previously, has an active infection or, if treatment had occurred more than 3 years ago, possible re-infection.

Alternative Name(s) 

Treponemal pallidum, Fluorescent Treponemal Antigen, Syphilis


Syphilis RPR ( RPR (Monitor) with Reflex to Titer)

Reference Range(s)


Clinical Significance

This is a non-treponemal screening test for syphilis. False positive results may occur due to systemic lupus erythematosus, leprosy, brucellosis, atypical pneumonia, typhus, yaws, pinta, or pregnancy. Monitoring of RPR is helpful in assessing effectiveness of therapy.


A positive RPR screen and a positive result on the FTA-ABS confirms the screening result and the affected person is diagnosed with syphilis.

A negative result on the treponemal test may mean that the initial RPR test was falsely positive. Further testing and investigation may be done to determine the cause of the false positive.


False-positive results have been associated in patients with infections, pregnancy, autoimmune disease, old age, Gaucher disease, and malignancy.

Alternative Name(s) 


To screen for APC-R associated with venous thromboembolic disorders.

This test will aid physicians in the assessment of risk of atrial fibrilation and cardioembolic stroke.

Cardio IQ Lp-PLA2 Activity

Clinical Significance

Lipoprotein-associated phospholipase A2 (Lp-PLA2), also known as platelet activating factor Acetylhydrolase, is an inflammatory enzyme that circulates bound mainly to low density lipoproteins and has been found to be localized and enriched in atherosclerotic plaques. In multiple clinical trials, Lp-PLA2 activity has been shown to be an independent predictor of coronary heart disease and stroke in the general population. Measurement of Lp-PLA2 may be used along with traditional cardiovascular risk factor measures for identifying individuals at higher risk of cardiovascular disease events. Clinical management may include beginning or intensifying risk reduction strategies. The activity assay is an enzyme assay run on an automated chemistry platform.

HDL cholesterol is inversely related to the risk for cardiovascular disease. It increases following regular exercise, moderate alcohol consumption and with oral estrogen therapy. Decreased levels are associated with obesity, stress, cigarette smoking and diabetes mellitus.

Most Popular
Total LDL and HDL cholesterol, in conjunction with a triglyceride determination, provide valuable information for the risk of coronary artery disease. Total serum cholesterol analysis is useful in the diagnosis of hyperlipoproteinemia, atherosclerosis, hepatic and thyroid diseases.

Clinical Significance

Bacterial sepsis constitutes one of the most serious infectious diseases. The detection of microorganisms in a patient's blood has importance in the diagnosis and prognosis of endocarditis, septicemia, or chronic bacteremia.


Aerobic culture, anaerobic culture. If culture is positive, identification will be performed at an additional charge (CPT code(s): 87076 or 87106 or 87077 or 87140 or 87143 or 87147 or 87149).
Antibiotic susceptibilities are only performed when appropriate (CPT code(s): 87181 or 87184 or 87185 or 87186).

Factor V (Leiden) Mutation is a point mutation that causes resistance of Factor V protein degradation by activated protein C (APC). This mutation is associated with increased risk of venous thrombosis.

Stroke is a condition caused by the sudden blockage or diminished blood supply to a part of the brain.  This changes/affects body functions controlled by the part of the brain, hence reduced response or no response to stimulation at all. Stroke mainly happens when/if these brain cells do not get oxygen and nutrients made available by the fresh supply of blood. Body cells, and brain cells may get inflamed or even die if they do not get enough oxygen and nutrients, one of the reasons why stroke leaves one permanently disabled.  

Statistics show that more than 129,000 Americans die from stroke each year, with approximately 795,000 people suffering new or recurrent stroke annually. This makes stroke the 5th leading cause of death in the United States. 65% of all stroke-related deaths occur in women. In addition to causing long-term disability in most survivors, at least 25% of them are at risk of suffering another stroke within five years. 

Types of Stroke  

  • Ischemic: This is the most common type of stroke, accounting for more than 87% of reported cases. It is mainly caused by a blocked artery to the brain (thrombotic stroke). This can occur as a result of a blood clot in a narrow artery, or if the clot (in other parts of the body) breaks off and travels to the brain, commonly known as an embolic stroke. 
  • Hemorrhagic stroke: This type of stroke occurs when/if a blood vessel ruptures, causing breeding in and around the brain. This could be as a result of a head injury (from an accident) or aneurysms. Aneurysms occur as a result of high blood pressure or a genetic defect.  This is the most dangerous type of stroke, which almost always leads to death.  

Risk Factors 

The most common risk factors include: 

  • Diabetes mellitus  
  • High blood pressure  
  • Dangerously high cholesterol levels  
  • Age (seniors have a risk)  
  • Hereditary genetics  
  • Race (African Americans have a higher risk of stroke when compared to Caucasians)  
  • Sex (more men suffer a stroke as compared to women, while more women succumb to it quickly)  
  • Sickle cell anemia   
  • Antiphospholipid antibody syndrome  
  • Leading an unhealthy lifestyle (lack of exercise, drug abuse, and unhealthy eating habits)   

Signs and Symptoms

Most people will have one or more mini strokes, commonly known as TIAs (Transient Ischemic Attacks), before having an actual one. These mini strokes should serve as a warning and a reason to seek medical attention as soon as possible. Symptoms of stroke can be persistent, with TIAs fading off within no time. The most common symptoms of TIA or Stroke include:  

  • Severe, unexplained headache  
  • Trouble talking, sudden loss of speech, and difficulties understanding what is being said  
  • Sudden loss of coordination, balance, and trouble walking  
  • Paralysis of the leg, arm, or face (on one side of the body), sudden weakness and numbness 
  • Unexpected difficulties in seeing with one or both eyes and blurred vision.   


Doctors mainly use non-laboratory testing for stroke diagnosis. These include several imaging tests, a neurological and physical exam. Researchers are, however, in the process of finding laboratory tests that could be used in stroke diagnosis, screening, treatment, and management. Stroke biomarkers may also come in handy in the future.  

Some of the feasible biomarkers that could be used in risk assessment include N-methyl-D-aspartate neuroreceptors (NMDAR), Lp-PLA2, and NT-PRoBNP. Antibodies to metalloproteinases (MMPs) and NR2A/2B are potential candidates for stroke diagnosis as well. A panel of biomarkers could be used in both risk assessment and diagnostic tools for stroke. All these are, however, in the research stage, hence, yet to be tested.  

Some lab tests may also be ordered to assess a patient’s risk. These include:  

More tests may be required to identify situations that could increase your risk. These include: